MAPT and early-onset autosomal dominant Alzheimer disease: In addition to such effects, Park et al. [17] have reported cilostazol reduces intracellular Aβ and phosphorylated tau levels in N2a cells stably expressing human APP Swedish mutation (N2aSwe cells), and in-line with these results, cilostazol significantly improved brain function such as spatial learning and memory in an experimental model of Alzheimer’s disease.